Frontline Treatment of Chronic Myelogenous Leukemia

There are currently three agents approved for the frontline treatment of patients with Philadelphia chromosome-positive chronic myelogenous leukemia, making an upfront treatment decision difficult. To address this, panelist explore possible first-line options and nuances of selecting therapies.

To view more from this discussion, visit http://www.onclive.com/peer-exchange/mds-cml